To my friends on the other side of the aisle, the fiscal conservatives, we need your voices.

If this program were going to the urban areas or maybe to the poorer people, we would hear an outcry from certain Members on the other side, but our farmers need the help too. When you waste money on an ag program, the people who are hurt the most are our smaller and family farmers, particularly, in this case, in the Middle West.

For years, my Republican friends in this Chamber accused the Obama administration—unfairly, in my mind—of picking winners and losers in the market. It was one of their favorite talking points. Here, we have the Trump administration literally picking winners and losers among American farmers. Sometimes the winners are not even American. Oftentimes, the losers are the small family farmers who need assistance the most.

I am so glad that my Democrat colleagues on the Agriculture, Nutrition, and Forestry Committee, especially Ranking Member STABENOW, have worked to inject some transparency into the agriculture relief program.

The Trump administration should be using the Market Facilitation Program to help those farmers most in need—period. The Trump administration needs to stop picking winners and losers and make sure all American farmers get the help they deserve.

## VETERANS

Mr. President, finally, on veteransthis is another one-when I look at what this administration is doing, and if every American knew all these things, Donald Trump wouldn't stand a chance. This one, I hope, will get out.

I talked a little bit about this yesterday. We all know that so many of our young men and women—my generation—went to Vietnam and risked their lives. Many of them gave their lives for our country. One of the worst aspects of things is that they were not treated as heroes when they came home.

I think America has made up for that now, but here is a way that we are not treating them well at all. Many of them were exposed to Agent Orange, and it became clear that many got sick from exposure to Agent Orange while fighting in Vietnam.

Well, what the VA has found is that certain illnesses are caused by exposure to Agent Orange, and they found that there are four more illnesses that have an Agent Orange link. But quietly and secretly, the Trump administration denied payments to over 60,000 veterans who had these illnesses and who received emergency care at non-VA facilities in 2017.

It has missed deadlines to expand the VA caregivers program to Vietnam and Korean war veterans, and there are some reports that the Trump VA hired doctors on probation, but what is galling at the moment is this Agent Orange situation and hiding the report.

Mulvaney, evidently, the Chief of Staff, just said quietly: We are not

funding it. It took a Freedom of Information Act action to reveal that they were cutting the money off for these folks.

They went to Vietnam. Some of them volunteered. Some of them were drafted. They got sick because of exposure to Agent Orange, and the Trump administration, which loves to have rallies with veterans, cuts the money off from them, saying that Mulvaney said we couldn't afford it.

These veterans could afford to risk their lives for us. We can afford to help them in their hour of need. I hope the administration will reverse its deci-

I vield the floor.

## RECESS

The PRESIDING OFFICER. Under the previous order, the Senate stands in recess until 2 p.m.

Thereupon, the Senate, at 12:48 p.m., recessed until 2 p.m. and reassembled when called to order by the Presiding Officer (Mr. PERDUE).

EXECUTIVE CALENDAR—Continued

The PRESIDING OFFICER. The Senator from Iowa.

Mr. GRASSLEY. Mr. President, I ask unanimous consent that I have the right to yield to Senator Collins at the end of my remarks.

The PRESIDING OFFICER. Without objection, it is so ordered.

PRESCRIPTION DRUG PRICING REDUCTION ACT

Mr. GRASSLEY. Mr. President, polls show a surprising interest of Americans in the high cost of prescription drugs. It seems to be an issue that unites Americans. I often point out that Washington is an island surrounded by reality. Here inside the Beltway, people are obsessed with partisan impeachment proceedings. It seems like morning, noon, and night, the relentless effort to unseat the President of the United States is a toxic strain of Potomac fever infecting Capitol Hill.

Now, if only Congress would channel every waking minute to fix problems in the real world, wouldn't that be wonderful? So let me provide a reality check. For people living in the real world, impeachment inquiry is not what keeps Americans up at night. It is not what wakes up moms and dads worried sick about paying for their child's insulin. It is not what drains the pocketbooks of seniors and takes a big bite out of people's paychecks. The issue that unites Americans from Maine, to Iowa, to Oregon is the sky-high prices that Americans and the taxpaying public are paying for prescription medi-

As chairman of the Senate Finance Committee, I am working in a bipartisan way to fix what is broken in our drug supply chain. In February, we called the heads of Big Pharma to testify before the Finance Committee.

Next, we heard from the largest pharmacy benefit managers to examine rebates and unravel the pricing supply chain. There was an awful lot of fingerpointing between the various interests about the soaring drug prices that Americans pay for pharmaceuticals. That finger-pointing, we heard in our committee. Finger-pointing doesn't decrease drug prices because the real problem is there is too much secrecy and not enough accountability in the industry of pricing drugs.

When drug prices grow by leaps and bounds, year after year, it is time to look under the hood. It is time to kick the tires along the drug supply chain and check the gauge on the competition. Why in the world is insulin, just as an example—a drug that has been on the market for nearly 100 years-doubling or tripling in price for patients in the United States? It is surely not that way in Europe.

We have gotten lots of feedback from patient advocates, healthcare providers, and free market proponents. The pushback from Big Pharma reveals that we are really on to something. Congress needs to take its foot off the brake. It is time to deliver real savings, and our bill will deliver real savings to consumers and to the taxpayers. It is time to pass reforms that will cut prescription drug costs for the American people.

Now, some of my colleagues may require a more blunt call to action so I want to use the two-by-four illustration. Join us and score a win for the American people. Otherwise, do nothing and risk being on the losing side of the ballot box next November.

At my annual 99 county meetings where I always hold a Q&A with whatever groups of constituents gather, I hear the same message from people all across the State of Iowa. They have family members and they have neighbors who struggle to pay for prescription management, to manage chronic health conditions, and to treat diseases. Thanks to breakthrough treatments and cures, Americans are living longer and healthier lives.

Many are beating the odds of a diagnosis that would have been a death sentence a generation ago. However, if a loved one is diagnosed with MS or diabetes or cystic fibrosis, no miracle cure will help if Americans can't afford to pay for their medicine. It will not help seniors if sky-high prices drain taxpayer-financed health programs like Medicare and Medicaid. Soaring drug prices are forcing too many Americans to skimp on other necessities or even ration their doses of prescriptions that they take.

Now, I just mentioned, as an example, cystic fibrosis. Last month, the FDA approved a promising new treatment for this progressive genetic disorder. Cystic fibrosis impacts about 30,000 Americans. There is nothing parents will not do to advocate for their child living with this condition. That is how I met one family from Iowa a few